The association between high-sensitivity C-reactive protein concentration and diabetic nephropathy: A meta-analysis

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 23, 2015, Pages 4558-4568

  Liu, Q ^a   Jiang, C Y ^a   Chen, B X ^a   Zhao, W ^a   Meng, D ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; High sensitivity C reactive protein; Meta analysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE;

ARTICLE; BODY MASS; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EFFECT SIZE; HUMAN; MACROALBUMINURIA; META ANALYSIS; MICROALBUMINURIA; SENSITIVITY ANALYSIS; SEX RATIO; SYSTEMATIC REVIEW; URINARY EXCRETION; ADULT; AGED; ALBUMINURIA; BLOOD; CASE CONTROL STUDY; DIABETIC NEPHROPATHIES; FEMALE; MALE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ALBUMINURIA; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84966341061     PISSN: 11283602     EISSN: 22840729     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. SHIRAISHI FG, STRINGUETTA BELIK F, OLIVEIRA E SILVA VR, MARTIN LC, HUEB JC, GONÇALVES RDE S, CARAMORI JC, BARRETI P, FRANCO RJ. Inflammation, diabetes, and chronic kidney disease: role of aerobic capacity. Exp Diabetes Res 2012; 2012: 750286.
2. GIUNTI S, BARIT D, COOPER M. Diabetic nephropathy: from mechanisms to rational therapies. Minerva Med 2006; 97: 241-262.
3. MACRAE J, NICASTRI A, CHEN C. Diabetic nephropathy without hyperglycemia. J Diabet Complications 1990; 4: 126-131.
4. ELMARAKBY AA SULLIVAN JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012; 30: 49-59.
5. ROMERO-AROCA P, MENDEZ-MARIN I, BAGET-BERNALDIZ M, FERNANDEZ-BALLART J, SANTOS-BLANCO E. Review of the relationship between renal and retinal microangiopathy in diabetes mellitus patients. Curr Diabetes Rev 2010; 6: 88-101.
6. NGUYEN D, PING F, MU W, HILL P, ATKINS RC, CHADBAN SJ. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006; 11: 226-231.
7. YAMAMOTO Y, KATO I, DOI T, YONEKURA H, OHASHI S, TAKEUCHI M, WATANABE T, YAMAGISHI S, SAKURAI S, TAKASAWA S, OKAMOTO H, YAMAMOTO H. Development and prevent ion of advanced diabet ic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-268.
8. SARAHEIMO M, TEPPO A-M, FORSBLOM C, FAGERUDD J, GROOP PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003; 46: 1402-1407.
9. NAVARRO-GONZÁLEZ JF MORA-FERNÁNDEZ C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
10. KANG ES, KIM HJ, AHN CW, PARK CW, CHA BS, LIM SK, KIM KR, LEE HC. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract 2005; 69: 151-159.
11. HANSEN TK, FORSBLOM C, SARAHEIMO M, THORN L, WADEN J, HOYEM P, OSTERGAARD J, FLYVBJERG A, GROOP PH, FINNDIANE STUDY G. Association between mannose-binding lectin, high-sensitivity Creactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia 2010; 53: 1517-1524.
12. NINOMIYA T, PERKOVIC V, DE GALAN BE, ZOUNGAS S, PILLAI A, JARDINE M, PATEL A, CASS A, NEAL B, POULTER N. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821.
13. STEHOUWER CD, GALL MA, TWISK JW, KNUDSEN E, EMEIS JJ, PARVING HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165.
14. JENKINS AJ, ROTHEN M, KLEIN RL, MOLLER K, ELDRIDGE L, ZHENG D, DURAZO-ARVIZU R, MCGEE D, LACKLAND D, THORPE SR, GARVEY WT, LYONS TJ; DCCT/EDIC Research Group. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabet Complications 2008; 22: 153-163.
15. DEFINITION W. diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva: World Health Organization, 1999.
16. WELLS G, SHEA B, O'CONNELL D, PETERSON J, WELCH V, LOSOS M, TUGWELL P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013.
17. OWNBY RL, CROCCO E, ACEVEDO A, JOHN V, LOEWENSTEIN D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530-538.
18. HOZO SP, DJULBEGOVIC B, HOZO I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
19. LAU J, IOANNIDIS JP, SCHMID CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
20. FENG RN, ZHAO C, SUN CH, LI Y. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS One 2011; 6: e18480.
21. EGGER M, SMITH GD, SCHNEIDER M, MINDER C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634.
22. AHLUWALIA TS, KHULLAR M, AHUJA M, KOHLI HS, BHANSALI A, MOHAN V, VENKATESAN R, RAI TS, SUD K, SINGAL PK. Common variants of inflammatory cytokine genes are associated wi th r isk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 2009; 4: e5168.
23. SHELBAYA S, AMER H, SEDDIK S, ALLAH A, SABRY I, MOHAMED T, EL MOSELY M. Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. Eur Rev Med Pharmacol Sci 2012; 16: 176-182.
24. CHOUDHARY N AHLAWAT RS. Interleukin-6 and C-react ive protein in pathogenesis of diabet ic nephropathy. Iran J Kidney Dis 2008; 2: 73.
25. ROOPAKALA MS, PAWAN HR, KRISHNAMURTHY U, WILMA DELPHINE SILVIA CR, ESHWARAPPA M, PRASANNA KUMAR KM. Evaluation of high sensitivity C-reactive protein and glycated hemoglobin levels in diabetic nephropathy. Saudi J Kidney Dis Transpl 2012; 23: 286-289.
26. NAVARRO JF, MORA C, MUROS M, GARCIA J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006; 21: 3428-3434.
27. NELSON CL, KARSCHIMKUS CS, DRAGICEVIC G, PACKHAM DK, WILSON AM, O'NEAL D, BECKER GJ, BEST JD, JENKINS AJ. Systemic and vascular inflammation is elevated in ear ly IgA and type 1 diabet ic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant 2005; 20: 2420-2426.
28. CHEN FQ, WANG J, LIU XB, MA XY, ZHANG XB, HUANG T, MA DW, WANG QY. Levels of inflammatory cytokines in type 2 diabetes patients with different urinary albumin excretion rates and their correlation with clinical variables. J Diabetes Res 2013; 2013: 138969.
29. EYILETEN T, SONMEZ A, SAGLAM M, CAKIR E, CAGLAR K, OGUZ Y, VURAL A, YENICESU M, YILMAZ MI. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010; 15: 225-229.
30. AVCI E, CAKIR E, CEVHER SC, YAMAN H, AGILLI M, BILGI C. Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. Ren Fail 2014; 36: 767-773.
31. TASLIPINAR A, YAMAN H, YILMAZ MI, DEMIRBAS S, SAGLAM M, TASLIPINAR MY, AGILLI M, KURT YG, SONMEZ A, AZAL O, BOLU E, YENICESU M, KUTLU M. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest 2011; 71: 606-612.
32. MASTEJ K ADAMIEC R. Neutrophil surface expression of CD11b and CD62L in diabetic microangiopathy. Acta Diabetol 2008; 45: 183-190.
33. SCHRAM MT, CHATURVEDI N, SCHALKWIJK C, GIORGINO F, EBELING P, FULLER JH, STEHOUWER CD. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes the EURODIAB Prospective complications study. Diabetes Care 2003; 26: 2165-2173.
34. SCHALKWIJK C, POLAND D, VAN DIJK W, KOK A, EMEIS J, DRÄGER A, DONI A, VAN HINSBERGH V, STEHOUWER C. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-357.
35. RIVERO A, MORA C, MUROS M, GARCIA J, HERRERA H, NAVARRO-GONZALEZ J. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci 2009; 116: 479-492.
36. LIANG YJ, SHYU KG, WANG BW, LAI LP. C-reactive protein activates the nuclear factor-êB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 2006; 40: 412-420.
37. HANRIOT D, BELLO G, ROPARS A, SEGUIN-DEVAUX C, POITEVIN G, GROSJEAN S, LATGER-CANNARD V, DEVAUX Y, ZANNAD F, REGNAULT V. C-reactive protein induces pro-and anti-inflammatory effects, including activation of the liver X receptor á, on human monocytes. Thromb Haemost 2008; 99: 558-569.
38. RETNAKARAN R, CULL CA, THORNE KI, ADLER AI, HOLMAN RR. Risk factors for renal dysfunction in type 2 diabetes UK Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839.
39. SCHAUMBERG DA, GLYNN RJ, JENKINS AJ, LYONS TJ, RIFAI N, MANSON JE, RIDKER PM, NATHAN DM. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 2005; 111: 2446-2453.
40. DEFRONZO R, SIMONSON D, FERRANNINI E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982; 23: 313-319.
41. SESMILO G, BILLER BM, LLEVADOT J, HAYDEN D, HANSON G, RIFAI N, KLIBANSKI A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiencyA randomized, controlled clinical trial. Ann Intern Med 2000; 133: 111-122.
42. TAKEDA T, HOSHIDA S, NISHINO M, TANOUCHI J, OTSU K, HORI M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003; 169: 155-158.